Tumor-Targeted Interleukin 2 Boosts the Anticancer Activity of FAP-Directed Radioligand Therapeutics-Reference-Cited by-同舟云学术

Tumor-Targeted Interleukin 2 Boosts the Anticancer Activity of FAP-Directed Radioligand Therapeutics

Published:2023-09-21 Issue:12 Volume:64 Page:1934-1940
ISSN:0161-5505
Container-title:Journal of Nuclear Medicine
language:en
Short-container-title:J Nucl Med

Author:

Galbiati Andrea,Dorten Paulina,Gilardoni Ettore,Gierse Florian,Bocci Matilde,Zana Aureliano,Mock Jacqueline,Claesener Michael,Cufe Juela,Büther Florian,Schäfers Klaus,Hermann Sven,Schäfers Michael,Neri Dario,Cazzamalli Samuele,Backhaus Philipp

Publisher

Society of Nuclear Medicine

Subject

Radiology, Nuclear Medicine and imaging

Reference44 articles.

1. Current research topics in FAPI theranostics: a bibliometric analysis;van den Hoven;Eur J Nucl Med Mol Imaging.,2023

2. 68Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer;Kratochwil;J Nucl Med.,2019

3. 68Ga-FAPI as a Diagnostic Tool in Sarcoma: Data from the 68Ga-FAPI PET Prospective Observational Trial

4. Histogenesis-specific expression of fibroblast activation protein and dipeptidylpeptidase-IV in human bone and soft tissue tumours

5. A phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer;Scott;Clin Cancer Res.,2003

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preclinical Evaluation of¹⁷⁷Lu-OncoFAP-23, a Multivalent FAP-Targeted Radiopharmaceutical Therapeutic for Solid Tumors;Journal of Nuclear Medicine;2024-09-12

2. Tumor-Homing Antibody-Cytokine Fusions for Cancer Therapy;OncoTargets and Therapy;2024-08

3. Molecular Evolution of Multivalent OncoFAP Derivatives with Enhanced Tumor Uptake and Prolonged Tumor Retention;Journal of Medicinal Chemistry;2024-07-30

4. Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein;Cancer Research Communications;2024-06-12

5. Targeted interleukin-2 enhances the in vivo anti-cancer activity of Pluvicto™;European Journal of Nuclear Medicine and Molecular Imaging;2024-04-02